Egfr-Mutation Detection In Vtx-1-Enriched Ctcs, Ctdna, And Comparison To Tumor In Patients With Non-Small Cell Lung Cancer (Nsclc).

e20525Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIu0027s) have shown dramatic clinical benefits when EGFR mutations are detected. These assays are mainly performed on tumor biopsies, which carry risks, are expensive and are not always successful. Moreover, secondary mutations, causing resistance to 1st u0026 2nd generation TKI’s develop during treatment and therefore mutations require ongoing monitoring. Circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) are promising for monitoring the patient over time and show enhanced sensitivity when combined1. The VTX-1 Liquid Biopsy System enables label-free capture of CTCs from blood and genomic assays downstream2. In this study, we demonstrate the sensitivity of a combined EGFR assay on VTX-1-enriched CTCs and ctDNA, using blood spiked with cancer cells u0026 DNA and then with NSCLC patients. Methods: NSCLC cells (A549: wt, H1975: L858R+ u0026 T790M+, HCC827: 19del+) were used to validate the assay. H1975 cells and HCC827 DNA w...